Table 2.
Univariable Cox proportional hazards regression for Event Free Survival and Overall Survival
| Variables | EFS | OS | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | IC (95%) | P | Hazard ratio | IC (95%) | P | |
| Age at diagnosis | ||||||
| ≥ 1 < 10 (ref) | – | – | – | – | – | – |
| < 1 ≥ 10 | 2.58 | 0.78;8.53 | 0.121 | 3.02 | 0.74; 12.25 | 0.121 |
| Histology | ||||||
| ARMS (ref) | – | – | – | – | – | – |
| ERMS | 0.63 | 0.19; 2.06 | 0.443 | 0.86 | 0.21; 3.46 | 0.831 |
| Tumor size | ||||||
| ≤ 5 cm (ref) | – | – | – | – | – | – |
| > 5 cm | 1.66 | 0.44;6.28 | 0.453 | 2.17 | 0.43; 10.87 | 0.344 |
| Primary site (location) | ||||||
| Favorable (ref) | – | – | – | – | – | – |
| Unfavorable | 1.11 | 0.32;3.80 | 0.867 | 1.14 | 0.27; 4.80 | 0.851 |
| COG Group | ||||||
| Low (ref) | – | – | – | – | – | – |
| Intermediate | 2.93 | 0.35;24.41 | 0.319 | 1.13 | 011; 10.98 | 0.914 |
| High | 9.76 | 1.04;91.19 | 0.046 | 11.59 | 1.19; 112.25 | 0.034 |
| VEGF score | ||||||
| 1–2 (ref) | – | – | – | – | – | – |
| 3–4 | 0.54 | 0.14;2.06 | 0.373 | 0.46 | 0.93; 2.31 | 0.349 |
| CD105/CD31 Ratio | ||||||
| < 0.9 (ref) | – | – | – | – | – | – |
| ≥ 0.9 | 5.31 | 0.75;46.25 | 0.090 | – | – | – |
| CD105/CD31 Ratio | ||||||
| < 1.3 (ref) | – | – | – | – | – | – |
| ≥ 1.3 | – | – | – | 5.89 | 1.18;29.2 | 0.030 |
(Ref Reference, IC interval confidence, COG Children’s Oncology Group, ERMS embryonal rhabdomyosarcoma, ARMS alveolar rhabdomyosarcoma, VEGF Vascular Endothelial Growth Factor, CD105 Endoglin). In boldface the values statistically significant